A single active catalytic site is sufficient to promote transport in P-glycoprotein by Orsolya Bársony et al.
1Scientific RepoRts | 6:24810 | DOI: 10.1038/srep24810
www.nature.com/scientificreports
A single active catalytic site is 
sufficient to promote transport  
in P-glycoprotein
Orsolya Bársony1,*, Gábor Szalóki1,*, Dóra Türk2, Szabolcs Tarapcsák1, Zsuzsanna Gutay-Tóth1, 
Zsolt Bacsó1, Imre J. Holb3,4, Lóránt Székvölgyi5, Gábor Szabó1, László Csanády6, Gergely  
Szakács2,7,† & Katalin Goda1,†
P-glycoprotein (Pgp) is an ABC transporter responsible for the ATP-dependent efflux of 
chemotherapeutic compounds from multidrug resistant cancer cells. Better understanding of the 
molecular mechanism of Pgp-mediated transport could promote rational drug design to circumvent 
multidrug resistance. By measuring drug binding affinity and reactivity to a conformation-sensitive 
antibody we show here that nucleotide binding drives Pgp from a high to a low substrate-affinity 
state and this switch coincides with the flip from the inward- to the outward-facing conformation. 
Furthermore, the outward-facing conformation survives ATP hydrolysis: the post-hydrolytic complex 
is stabilized by vanadate, and the slow recovery from this state requires two functional catalytic sites. 
The catalytically inactive double Walker A mutant is stabilized in a high substrate affinity inward-open 
conformation, but mutants with one intact catalytic center preserve their ability to hydrolyze ATP 
and to promote drug transport, suggesting that the two catalytic sites are randomly recruited for ATP 
hydrolysis.
P-glycoprotein (Pgp) is a primary active membrane transporter of the ABC (ATP Binding Cassette) protein 
superfamily. It is the first human ABC transporter discovered to be responsible for the increased efflux of chem-
otherapeutics from multidrug resistant cancer cells1,2. Pgp is referred to as a “hydrophobic vacuum cleaner”, 
because it is believed to extract its substrates directly from the inner leaflet of the plasma membrane3. This molec-
ular mechanism of action provides an incredibly efficient efflux of a vast array of hydrophobic drugs, ensuring the 
survival of cancer cells despite toxic chemotherapy (for reviews see4,5).
Based on biochemical experiments and the commonality of various mammalian and bacterial ABC trans-
porter structures it is generally believed that the fundamental molecular mechanism of substrate transport is 
shared among ABC transporters6–8. From bacteria to humans, ABC transporters are composed of at least two 
membrane-embedded transmembrane domains (TMDs) and two cytoplasmic nucleotide binding domains 
(NBDs). The TMDs define the substrate binding sites and the translocation pathway, and the NBDs bind and 
hydrolyze ATP. The TMDs are connected to the NBDs by intra-cytosolic loop (ICL) domains, which transfer 
signals to coordinate ATP binding and hydrolysis with substrate transport7. The NBDs contain several evolution-
arily conserved sequences, including the Walker A and B motifs that are commonly found in nucleotide-binding 
proteins9, and the so-called signature sequence (C-loop or LSGGQ motif), which is unique to the ABC protein 
family10. The conserved motifs form two composite catalytic sites in which the ATP molecules are sandwiched 
between the Walker A and Walker B motifs of one NBD and the signature sequence of the contralateral NBD11.
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Crystal structures of full-length ABC transporters have revealed two major conformations: in the absence of 
nucleotides, the NBD dimers are dissociated and the TMDs adopt an inward-facing conformation6,12. Nucleotide 
binding to the dissociated NBDs13 induces formation of two composite catalytic sites at the interface of a tight 
head-to-tail NBD1/NBD2 heterodimer, glued together by the two ATP molecules. Concomitantly with NBD 
dimer formation the TMDs flip into an outward-facing conformation7,8. Only one of two gates is open at any 
time: in the inward-facing conformation the cytoplasmic gate of the translocation pathway is open, whereas the 
extracellular gate is closed. Conversely, in the outward-facing conformation the cytoplasmic gate is closed and 
the transported drug is free to dissociate to the extracellular compartment. The above conformational transitions 
are accompanied by the switch of the affinity of the substrate binding sites from high- to low-affinity to ensure 
substrate transport against the concentration gradient14,15.
Notably, the recently solved structure of the antibacterial peptide ABC transporter McjD is occluded on 
both sides of the membrane. This conformation, termed nucleotide-bound outward occluded, probably rep-
resents a transition intermediate between the outward-open and inward-open TMD conformations of ABC 
exporters16. Repeated formation and disruption of the NBD dimer is generally agreed to involve the coopera-
tive, ATP-dependent interaction of the NBDs, but because the resolved structures do not represent all phases of 
the transport cycle the exact sequence of events is unknown. While the major principles of the ATP-dependent 
transport mechanism are shared among ABC transporters, details of the coupling of the TMD transitions to the 
ATPase cycle may differ in different subclasses of ABC exporters17.
A spate of biochemical data supports that the molecular mechanism of Pgp follows the above alternating 
access scheme (reviewed in18,19). Still, despite the availability of the mouse6,20 and the C. elegans12 Pgp structures, 
the molecular mechanisms linking ATP binding and/or hydrolysis to the association and dissociation of NBDs 
and to conformational changes occurring in the TMDs are not fully understood. The catalytic cycle is driven by 
ATP hydrolysis, which may happen at either of the two functionally symmetrical composite nucleotide binding 
sites. How ATP hydrolysis is coordinated between the two NBDs, and whether Pgp hydrolyses one or two (or 
more) ATP molecules per each transported substrate are not known. Experiments attempting to explain the 
sequence of molecular events that lead to the ATP-dependent conformational switch and the change of substrate 
binding affinity have produced competing models21.
Conformational transitions in Pgp that occur during transport-associated ATP hydrolysis can be detected 
by differential immunoreactivity to the monoclonal antibody UIC222. The complex epitope of UIC2 consists of 
multiple extracellular loops of Pgp23,24, which undergo conformational changes when the TMDs rearrange to bind 
and release the transported substrate. It was shown that UIC2 binding to Pgp is increased in the presence of trans-
ported substrates, ATP-depleting agents, or by mutational inactivation of both nucleotide-binding domains22, 
suggesting that UIC2-detectable conformational transitions are driven by binding and unbinding of nucleo-
tides25. In the present study we correlated UIC2-reactivity with drug binding affinity for wild-type and mutant 
Pgp variants in permeabilized cells to elucidate the link between ATP binding, hydrolysis and the conformational 
rearrangements responsible for switching the affinity of the substrate binding sites during substrate transport.
Results
Nucleotide binding switches Pgp into the outward facing conformation. Gentle permeabilization 
of cells allows selective modulation of the intracellular milieu while preserving membrane integrity and the func-
tion of transmembrane transporters. This experimental setup has been used before to synchronize Pgp molecules 
in an ATP-free, high UIC2-affinity conformation25. Similarly to the results obtained by Druley and co-work-
ers25, replenishing the cells with ATP/Mg2+ shifted Pgp into a low UIC2-affinity conformation in a concentration 
dependent manner (Fig. 1a). The apparent affinity of ATP for competing UIC2 labeling (KA, Supplementary 
Table S1) was found to be comparable with reported KM values for ATP hydrolysis26,27 as well as with our results 
obtained in membrane samples prepared from Pgp+ NIH 3T3 cells (Supplementary Fig. S1).
AMP-PNP, a non-hydrolysable ATP analogue also induced a conformation change in the transmembrane 
domains resulting in a concentration dependent decrease in UIC2 reactivity (Fig. 1c). When ATP was added in 
the absence of Mg2+ (ATP + EDTA; Fig. 1b) or on ice (Fig. 1d), i.e., under conditions that prevent ATP hydrolysis, 
the conformational change driving Pgp into a UIC2-dim state was observed at significantly higher nucleotide 
concentrations (Supplementary Table S1).
The transport and ATPase cycle of Pgp is inhibited by phosphate-mimicking anions, such as orthovanadate 
(Vi), which can block the protein by stably replacing the cleaved gamma phosphate. The complex consisting of 
Pgp, ADP and vanadate (Pgp-ADP-Vi) is formed only under conditions that allow hydrolysis of at least one ATP 
molecule, and is generally accepted to closely mimic the conformation of a transition state28. Of note, consist-
ent with the formation of the Pgp-ADP-Vi complex, addition of vanadate increased the apparent affinity under 
hydrolysis conditions (37 °C, presence of ATP/Mg2+, Fig. 1a, Supplementary Table S1). However, when ATP 
hydrolysis was prevented, the apparent affinity was not influenced at all by Vi (Fig. 1b–d), confirming that ATP 
hydrolysis and the subsequent release of the γ-phosphate is a prerequisite for the formation of the Pgp-ADP-Vi 
complex29.
Unilateral mutation of the Walker A lysine residues allows ATP binding and substrate-stimulated 
ATP hydrolysis. The Walker A motif (GXXGXGKS/T), also known as the P-loop (phosphate-binding loop), 
forms extensive bonds with the terminal phosphates of the bound nucleotide9. Mutation of the highly conserved 
lysine residue to methionine was shown to abolish ATPase activity of several ABC transporters30–32. To study the 
effect of mutations of the Walker A lysines in NBD1 (K433) and NBD2 (K1076) of Pgp on nucleotide-induced 
TMD conformational flexibility, we engineered mammalian cell lines (NIH 3T3 and MDCKII) stably expressing 
wild-type (WT), K433M, K1076M, or K433M/K1076M P-glycoprotein using a Sleeping Beauty transposon-based 
gene delivery system. Consistent with previous studies that showed that single Walker A mutations allow 
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nucleotide binding32, UIC2-reactivity of the K433M and K1076M variants decreased in the presence of AMP-PNP 
and ATP (Fig. 2a–c). Earlier we have shown the fluoroaluminate-dependent labeling of K433M and K1076M Pgp 
with [α -32P]-8-azido-ATP33. Here we find that addition of vanadate results in a 5–10-fold increase in the appar-
ent affinity of the single mutants to ATP (Fig. 2b,c). Because complex formation with vanadate requires prior 
hydrolysis of ATP, these effects of vanadate indicate that Pgp is capable of ATP hydrolysis despite the mutation of 
a single Walker A lysine residue. In contrast, simultaneous mutation of both lysine residues resulted in a stable 
UIC2-binding conformation, which could not be reverted by nucleotides (Fig. 2d).
The turnover rate of Pgp’s catalytic cycle is accelerated in the presence of transported substrates 
(substrate-stimulated ATPase activity)27. Kinetic analysis of the formation of the BeFx- or Vi-trapped complexes 
showed that progressive accumulation in the low-UIC2-affinity trapped transition state occurs at comparable 
rates in WT or single mutant Pgps. Accumulation in the trapped complex was accelerated by Pgp substrates (e.g. 
verapamil, vinblastine, rhodamine 123) or competitive inhibitors (e.g. cyclosporine A) both in WT and single 
Walker A mutant Pgp variants (results are shown for vinblastine, see Fig. 3a,c,d), while the apparent affinity for 
ATP did not change even at high substrate concentrations (up to 200 μM vinblastine, see Fig. 3b). The effect of 
transported substrates on the rate of formation of the trapped transition state complex was identical in the WT 
and the single mutant Pgp variants (Supplementary Table S3). These data suggest that despite the mutation of a 
single critical Walker A lysine residue, the catalytic cycle can progress to the step arrested by phosphate mim-
icking anions. The relatively long t1/2 values of BeFx (~120 s, see Fig. 3 and Supplementary Table S3) and Vi trap-
ping (t1/2 = 235.2 ± 52.2 s; n = 6) compared to the total cycle time which is on the order of 100 ms suggest that 
formation of a stable post-hydrolysis complex by phosphate mimicking anions is an extremely low-probability 
event, likely reflecting the very short time window of the vanadate- or BeFx-“sensitive” state in each cycle, that is 
between dissociation of the cleaved phosphate and disassembly of the NBD dimer. Thus, similarly to WT Pgp, 
single Walker A mutant Pgp variants can not only hydrolyze ATP, but pass on average ~1200–2500 cycles before 
trapping by BeFx or vanadate occurs. Consistently with this turnover, single mutants retain a weak, but significant 
verapamil stimulated ATPase activity that can be detected in membrane samples prepared from NIH 3T3 cells 
expressing the transporter at high levels (Supplementary Fig. S2).
Figure 1. UIC2 mAb binding to Staphylococcus alpha toxin permeabilized NIH 3T3 cells expressing wild-
type Pgp in the presence of ATP/Mg2+ (a) ATP in the absence of Mg2+ (b) AMP-PNP/Mg2+ (c) or ATP/Mg2+ 
at 4 °C (d). Permeabilized cells were treated with nucleotides at different concentrations for 20 min and then 
labeled with UIC2-A647 for another 30 min (a–c) or 40 min (d) without washing out the nucleotides. In case of 
Vi treatment un-trapped nucleotides were washed out in the presence of Vi. UIC2-A647 fluorescence intensities 
were plotted as a function of nucleotide concentration and fitted with a four parameter Hill function to 
determine the apparent affinities of nucleotide binding (KA) and Hill slope values (see Materials and Methods).
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The rate of dissociation of the Vi-trapped complex is decreased by single Walker A mutations. 
Although the Vi-trapped species represent a dead-end of the catalytic reaction cycle, we wondered if the eventual 
release of the trapped nucleotide could be detected by an increase of UIC2 reactivity. Following the removal of 
uncomplexed Vi, complete time-dependent recovery of the UIC2-reactive state corresponding to the release of 
nucleotides was indeed observed (Fig. 4b). The half-life of Pgp-ADP-Vi complexes was 75.1 ± 5.9 min, in good 
agreement with literature data34,35. Release of the tightly bound nucleotide was temperature dependent (Fig. 4a,b), 
but was not influenced by the presence of ATP and transported substrates such as vinblastine or verapamil (not 
shown). UIC2 binding to the mutant Pgp variants was not restored in the time frame of the experiment (up to 
4 hours), suggesting that mutation of a single Walker A residue increases the life time of the vanadate-trapped 
complex.
Single Walker A mutants are transport-competent. Because single Walker A mutants were found 
to exhibit substrate-stimulated ATP hydrolytic activity (Fig. 3 and Supplementary Fig. S2), we next set out to 
determine whether they are also capable of promoting substrate transport. We compared the accumulation of 
calcein in both NIH 3T3 and MDCK cells expressing WT or mutant Pgp. Despite comparable expression levels, 
the Pgp-variant missing both Walker A lysine moieties (MM) was unable to hinder accumulation of calcein in 
the cells, whereas cells transfected with the single mutants showed a cyclosporine A-sensitive reduction in calcein 
fluorescence (Fig. 5a. and Supplementary Fig. S3). Reduction of intracellular calcein levels is a result of uphill 
transport activity which, by thermodynamic arguments, must be driven by ATP hydrolysis. To provide a quanti-
tative measure of this residual transport activity, we determined the first order rate constants (k) of rhodamine123 
(R123) efflux36 from cells expressing wild-type or mutant Pgp at comparable levels (Fig. 5b,c). In agreement with 
the data obtained with the calcein assay, single mutants showed significant R123 efflux activity, while the dou-
ble mutant was inactive (Fig. 5d,e). In line with the relatively weak transport activity, single mutants conferred 
resistance against the cytotoxic effect of vinblastine (Supplementary Fig. S4). Collectively, these results suggest 
that single Walker A mutants retain a residual transport activity of ~15% of WT, whereas the double mutant is 
not transport competent.
Figure 2. UIC2 mAb binding to single or double Walker A mutant Pgp variants in permeabilized cells in the 
presence of AMP-PNP/Mg2+ (a) or ATP/Mg2+ (b–d) in the absence or presence of Vi. Permeabilized cells were 
treated with nucleotides at different concentrations for 20 min and then labeled with UIC2-A647 for another 
30 min without washing out the nucleotides. In case of Vi treatment un-trapped nucleotides were washed out in 
the presence of Vi. UIC2-A647 fluorescence intensities were plotted as a function of nucleotide concentration 
and fitted with a four parameter Hill function to determine the apparent affinities of nucleotide binding (KA) 
and Hill slope values (see Materials and Methods).
www.nature.com/scientificreports/
5Scientific RepoRts | 6:24810 | DOI: 10.1038/srep24810
Figure 3. Kinetics of the formation of the BeFx-trapped species in case of wild-type (a) and single mutant (c,d) 
Pgp expressing cells. Permeabilized cells were incubated with 100 μM (for wild-type) or 500 μM (for K433M and 
K1076M) ATP/Mg2+ and BeFx (200 μM BeSO4 and 1 mM NaF) in the presence or absence of 50 μM vinblastine 
at 37 °C and samples were taken at different time points. Panel (b) shows the effect of 200 μM vinblastine on 
the apparent nucleotide affinity of wild-type Pgp. Permeabilized cells were treated with BeFx and different 
concentrations of ATP/Mg2+ in the presence or absence of 200 μM vinblastine for 20 min at 37 °C. UIC2-A647 
labeling was carried out following the washout of ATP/Mg2 in the maintained presence of BeFx.
Figure 4. Recovery of UIC2 labeling of wild-type and single Walker A mutant Pgp. (a) Staphylococcus 
aureus alpha toxin-permeabilized NIH 3T3 cells expressing wild-type or single Walker A mutant Pgp 
were incubated with ATP and 500 μM vanadate (Vi) to induce the formation of trapped Pgp-species. 
UIC2 mAb labeling was carried out after a 120-minute incubation at the indicated temperatures in Vi-free 
solution containing 50 μM NEM in the absence of ATP. (b) Time-dependent recovery of the UIC2-binding 
conformation of wild-type Pgp. Aliquots washed for various time intervals in Vi- and ATP-free solution 
containing 200 μM NEM were subsequently labeled with UIC2 mAb; washing and labeling were carried out 
either at 4 °C or at 37 °C.
www.nature.com/scientificreports/
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Mutation of the critical Walker A lysines results in increased drug binding affinity. Consistently 
with the Pgp-mediated efflux of vinblastine-bodipy (VBL-BPY), cells expressing WT Pgp show significantly lower 
levels of intracellular fluorescence as compared to Pgp− cells when incubated with this fluorescent drug (Fig. 6, 
b vs. a). ATP-depleted cells overexpressing wild-type Pgp sequester VBL-BPY in the plasma membrane (Fig. 6c). 
Strikingly, plasma membrane sequestration of VBL-BPY was also observed in cells transfected with either single 
or double Walker A mutant Pgp variants (for double Walker A mutant see Fig. 6d). Addition of cyclosporine A 
(CsA), a competitive inhibitor of Pgp, prevented plasma membrane accumulation of VBL-BPY (Fig. 6e), suggest-
ing that the enrichment of VBL-BPY in the plasma membrane is in each case due to its high-affinity binding to 
Pgp.
Figure 5. Functional expression of wild-type and Walker A mutant human Pgp variants in MDCK cells.  
(a) Cells were incubated with 0.1 μM calcein-AM with or without the Pgp-inhibitor cyclosporin A (CsA, 10 μM) 
for 30 minutes. Bars show the relative increase of calcein accumulation caused by CsA (means of 3 independent 
experiments ± SD). (b) Mean fluorescence of Pgp-expressing cells stained with the anti-Pgp 15D3-A647 
monoclonal antibody, showing comparable expression of Pgp variants in MDCK cells. *P < 0.05, **P < 0.01, 
***P < 0.001. In panel (a) samples were compared to the Pgp non expressing MDCK cells, while in panel (b) the 
samples were compared to the wild-type Pgp (WT) expressing cells. (c) Western blot analysis of Pgp expression 
using a monoclonal anti-Pgp mAb (G-1, Santa Cruz Biotechnology Inc.). (d) Time dependent efflux of R123 
from preloaded cells. Preloaded cells were incubated at 37 °C; during the first 5 min the fluorescence intensity 
of the cells was measured continuously and the values were averaged for 10 s intervals. At later time points 
fluorescence intensity distribution histograms were measured and their median fluorescence intensities were 
determined. (e) First order rate constants of the exponential curves fitted to the R123 efflux data (mean ± SD 
of three independent experiments). Significant differences compared to the non-transfected MDCK cells are 
shown by **P < 0.01.
www.nature.com/scientificreports/
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To quantify the fraction of substrate-bound Pgp molecules in the membrane, Pearson’s cross-correlation 
coefficients were calculated between the VBL-BPY and 15D3 anti-Pgp antibody signals in single optical slices 
of apical membrane surfaces. Since the antibody staining was unchanged in the course of the treatments, the 
cross-correlation coefficients depend mostly on VBL-BPY binding to Pgp. In cells expressing double Walker 
A mutant Pgp (Fig. 7d) large cross-correlation coefficients of close to unity (~0.8) indicate that the majority of 
Pgp molecules are in high substrate affinity conformation. Single Walker A mutants also exhibited somewhat 
increased drug binding compared to the WT (Fig. 7b,c), but this binding was fully suppressed by transition state 
analogs, e.g. vanadate (Fig. 7b,c). Furthermore, ATP depletion by Na-azide or prevention of ATP binding by NEM 
treatment29 shifted both single mutant and WT Pgp variants into the substrate binding conformation, as reflected 
by increased co-localization of VBL-BPY and Pgp molecules in the plasma membrane (Fig. 7a–c). Remarkably, 
the high substrate affinity of double mutant Pgp was not affected by any of the above treatments (Fig. 7d).
AMP-PNP binding is sufficient to switch Pgp from high to low drug affinity conformation. In 
permeabilized cells ATP depletion synchronized WT Pgp molecules in a high drug binding affinity conformation, 
as indicated by VBL-BPY sequestration in the plasma membrane (Fig. 8a, brown bar). Suppression of membrane 
fluorescence by CsA confirmed that drug accumulation in the membrane was indeed due to tight binding of 
VBL-BPY to Pgp (Fig. 8a, orange bar). This tight binding of VBL-BPY to Pgp was reversed in the presence of 
ATP and vanadate (Fig. 8a, ocher bar), consistent with the low drug binding affinity of the transition state com-
plex37. Strikingly, incubation of permeabilized cells in 5 mM AMP-PNP also resulted in a significant decrease in 
the co-localization of VBL-BPY and Pgp, indicating that ATP hydrolysis is not required for the affinity switch 
responsible for the release of the transported substrate (Fig. 8a, last bar). AMP-PNP treatment resulted in a sim-
ilar, although smaller, reduction of VBL-BPY binding to the single mutants (Fig. 8b). In contrast, simultaneous 
mutation of both Walker A lysine residues resulted in a permanent high drug binding affinity conformation, 
which could not be reversed by the addition of nucleotides (Fig. 8b).
Discussion
Based on crystal structures and a wealth of biochemical and biophysical data it is generally accepted that ABC 
transporters adopt at least two discrete conformations along their transport cycle. The switch between the 
Figure 6. Accumulation of Bodipy FL Vinblastine (VBL-BPY) in the apical plasma membrane of energy 
deprived wild-type (WT) Pgp expressing and double Walker A mutant (K431M/K1076M) Pgp expressing 
MDCK cells reveals the stabilization of a high-affinity substrate binding Pgp conformation. VBL-BPY 
(green) and anti-Pgp 15D3-Alexa647 mAb (15D3-A647; red) staining of confluent non-transfected MDCK cells 
(a) wild-type Pgp-expressing (b,c) and Walker A mutant (K431M/K1076M) Pgp expressing MDCK cells (d,e). 
ATP depletion was induced by 30 min pre-treatment with 10 mM Na-azide and 8 mM 2-deoxyglucose treatment 
(c). A non-fluorescent competitive Pgp inhibitor CsA (10 μM) was added 10 min before VBL-BPY and antibody 
staining (e). Inserts show the apical membrane surface of one cell. Bar: 10 μm.
www.nature.com/scientificreports/
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NBD-dissociated, inward-facing and the NBD-associated, outward-facing states involves a series of conforma-
tional changes which ultimately result in the reduction of substrate binding affinity required for uphill substrate 
transport. The exact molecular mechanisms that link nucleotide binding to the association and dissociation of 
NBDs and to the conformational changes of the TMDs are not fully understood. Our aim was to capitalize on 
the unique property of UIC2, a conformation-sensitive monoclonal antibody which recognizes a complex extra-
cellular Pgp epitope, to follow the conformational changes which occur in the TMDs. UIC2 distinguishes two 
conformations of Pgp, which can be studied by modulating intracellular ATP-levels in Staphylococcus aureus 
alpha-toxin-permeabilized cells overexpressing Pgp25: the UIC2-dim and UIC2-reactive conformations corre-
spond to the outward- and inward facing conformations observed in ATP-bound and nucleotide-free crystal 
structures, respectively. In addition, we monitored the nucleotide-dependent switch in drug binding affinity using 
a fluorescent Pgp substrate analog. Together, these assays allowed us to elucidate the link between ATP binding, 
hydrolysis and the conformational rearrangements responsible for switching the affinity of the substrate binding 
sites during substrate transport.
The timing of the conformational change which results in the decrease of drug binding affinity has been a 
matter of much debate. The “ATP switch model” predicts that ATP binding induces dimerization of the NBDs, 
which then triggers conformational changes resulting in the decrease of drug binding affinity; whereas the 
dissociation of the NBD resets the transporter for the next cycle38–42. In accordance with the above model the 
AMP-PNP-bound state of Pgp was reported to show reduced binding of vinblastine43,44. In some studies tran-
sition from the high to the low substrate affinity state was found to be triggered by nucleotide occlusion (i.e. 
tight binding) within the formed NBD dimer42,45,46. In contrast, other studies found that the conformational 
switch coupled to the change in drug binding affinity is driven by ATP hydrolysis47–49 or by the relaxation of a 
high-energy catalytic site conformation generated by the hydrolysis step28. These conflicting data may be due to 
the inherent limitations of the different experimental approaches such as the low labeling stoichiometry and the 
Figure 7. Pearson’s cross-correlation coefficients between the intensity distributions of cell-surface BODIPY FL 
Vinblastine (VBL-BPY) and 15D3-Alexa-647 labeling calculated for wild-type (a) single K433M (b); K1076M 
(c) and double Walker A mutant Pgp variants (d) expressed in MDCK cells. Cells were pre-treated for 30 min 
at 37 °C with 10 μM cyclosporine A (CsA), 2 mM vanadate (Vi), 50 μM N-ethyl-maleimide (NEM), or 10 mM 
Na-azide and 8 mM 2-deoxy D-glucose (ATP depletion), and then further incubated with VBL-BPY and 
15D3-A647 anti-Pgp antibody for another 30 min at 37 °C. Significant differences compared to the wild-type’s 
untreated control are shown by ***P < 0.001, **P < 0.01, or *P < 0.05 and those compared to the untreated 
control of the respective cell line by: †††P < 0.001, ††P < 0.01, or †P < 0.05. The untreated controls of the single 
and double mutants were also significantly different from each other (P < 0.01).
www.nature.com/scientificreports/
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variable labeling efficiency of photoaffinity reagents, as well as the difficulty of quantifying binding affinity of 
highly lipophilic compounds to transmembrane transporters50,51.
In view of the intimate association of Pgp with the lipid bilayer in which it is embedded, and from which it 
harvests its substrates, it is worth noting that the confocal microscopic fluorescence co-localization assay and the 
UIC2 assay shown here characterize the transporter in its natural plasma membrane environment. Although the 
UIC2 assay is an indirect method for measuring the apparent affinities of nucleotides to Pgp, our experimental 
system is clearly capable of discriminating between distinct steps of the ATPase cycle such as nucleotide binding 
or ATP hydrolysis. Our results demonstrate that AMP-PNP binding is sufficient to induce the conformational 
switch corresponding to the transition from the inward to the outward facing conformation (Fig. 1c). Using the 
same experimental setup, we also show that binding of AMP-PNP switches Pgp into the low drug binding affinity 
state (Fig. 8a). The simultaneous drop in the UIC2- and drug-binding affinities suggests that the high-to-low 
switch in drug binding affinity might coincide with the transition from the inward- to the outward-facing confor-
mation, but in any case precedes ATP hydrolysis (Figs 1,2 and 8.).
Residues of the Walker motifs in each NBD, together with the signature sequence of the contralateral NBD, 
directly participate in nucleotide-dependent dimerization of the two NBDs and ATP hydrolysis. How ATP hydrol-
ysis is coordinated between the two NBDs, and whether Pgp hydrolyses one or two (or more) ATP molecules per 
each transported substrate are not known. In diverse ABC transporters, mutations of the conserved Walker A 
lysine reduce ATPase activity to very low levels30–32,52–54. The two nucleotide binding domains of Pgp were shown 
to be functionally equivalent and the integrity of both catalytic centers is generally believed to be needed for 
transport, because inactivation of a single NBD results in inhibition of ATPase and transport activities29,34,55.
We confirm that mutation of both Walker A lysine residues inactivates Pgp (Fig. 5 and Supplementary 
Fig. S3): as indicated by the lack of ATP-triggered conformational changes, the transporter is essentially fro-
zen in the UIC2-reactive inward-open state (Fig. 2) characterized with high drug binding affinity (Figs 6–8). 
Intriguingly, however, our data show that nucleotide binding to single Walker A mutants triggers the same 
inward-to-outward conformational switch (Fig. 2a), and the concomitant drop in drug binding affinity (Figs 7 
and 8), as observed for the WT protein. Furthermore, we demonstrate that vanadate exerts the same effect on 
the UIC2 binding curves of the WT and the unilateral Walker A mutant Pgp variants. Since vanadate-dependent 
trapping is an extremely low-probability event, formation of the stable Vi-trapped complex (Fig. 3), as well as the 
significant left shift of the UIC2 binding curves in the presence of Vi (Fig. 2b,c), can only be explained if single 
Walker A mutants are catalytically competent. Admittedly, this result is opposed to prevailing views insisting on 
the requirement of two intact nucleotide binding domains for ATP hydrolysis by Pgp28. While our experimental 
system has several limitations (binding and hydrolysis of ATP is measured indirectly, by monitoring the binding 
of a conformation sensitive antibody to a complex extracellular epitope of Pgp in semipermeabilized cells), we 
note that the majority of the studies reporting the inactivating effect of single Walker A mutations have been 
performed using heterologous expression systems such as Sf932,56, Saccharomyces cerevisiae57 or purified and 
reconstituted proteins52,57,58. It is known that the plasma membrane composition influences the catalytic activ-
ity of ABC transporters, and that membrane cholesterol amounts influence Pgp activity59,60. Since membrane 
Figure 8. BODIPY FL Vinblastine (VBL-BPY) binding to wild-type Pgp in permeabilized NIH 3T3 cells (a) 
and to Walker A mutant Pgps in permeabilized MDCK cells (b). Cells permeabilized by Staphylococcus alpha 
toxin (a) or Streptolysin O (b) were treated with different concentrations of CsA, ATP/Mg2++ vanadate (Vi) or 
AMP-PNP/Mg2+ followed by co-staining with VBL-BPY and 15D3-A647. The ratio of the VBL-BPY and 15D3-
A647 fluorescence intensity was determined in pixels representing the plasma membrane, selected on the basis 
of 15D3-A647 fluorescence intensity exceeding the threshold of 300. Nucleotide-treated samples were compared 
to permeabilized ATP-depleted cells (0 mM nucleotide); the values are means ± SD of three independent 
experiments (***P < 0.001).
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cholesterol levels are significantly lower in lower eukaryotes60,61, it may be that the low ATPase activity of the 
single Walker mutants was missed due to the different plasma membrane composition of the heterologous expres-
sion systems, or artefacts related to the solubilization, purification and reconstitution of the proteins62. We show 
that the single Walker A mutants show drug-stimulated nucleotide hydrolysis (Fig. 3 and Supplementary Fig. S2), 
decrease the intracellular accumulation of calcein (Fig. 5a), promote R123 efflux (Fig. 5d–e) and offer moderate 
protection against cytotoxic Pgp substrates (Supplementary Fig. S4). Taken together, our data indicate that, in 
contrast to prevailing views, single-site Walker A mutant Pgp molecules retain a weak, but significant uphill 
transport activity, a phenomenon which cannot be explained other than through coupling to repeated cycles of 
ATP hydrolysis.
Formation of the vanadate-trapped species occurs with comparable rates in WT and single mutant Pgp 
(Fig. 3), suggesting that the fraction of time the working transporter spends in the Vi-sensitive posthydrolytic 
state is similar for WT and single mutant Pgp. Interestingly however, the rate of disassembly of the Vi-trapped 
complex is greatly reduced in the single mutants (Fig. 4a). Assuming that the trapped complex harbors an ATP 
in the non-committed site, one might speculate that disassembly of the complex happens only upon eventual 
hydrolysis of that ATP. This process might happen at a rate of ~1 per hour in a non-committed wild-type catalytic 
center (cf., Fig. 4b), but never at all in a center disabled by a Walker A mutation (Fig. 4a). Taken together our 
experiments carried out with single Walker A mutants suggest that while one hydrolysis event is sufficient to reset 
the high-substrate affinity inward facing conformation in the absence of Vi, dissociation of the Vi-trapped com-
plex also requires the hydrolytic activity of the contralateral site, supporting the possibility that the Vi-trapped 
complex may not mimic a true catalytic transition state in case of Pgp. However, much further work will be 
required to fully understand these details.
Importantly, the fact that single Walker A mutations allow residual transport is incompatible with a model 
in which two ATP molecules must be hydrolyzed in each cycle. Our results are also difficult to reconcile with 
models suggesting that the two NBDs hydrolyze ATP in a strictly alternating order28,47. If the NBDs were indeed 
recruited in a strictly alternating fashion, every second ATP would have to be processed by the mutant catalytic 
center, causing the cycle to stall. Instead, our results indicate that the wild-type catalytic site can hydrolyze ATP 
in repeated cycles without hydrolysis at the other NBD. The simplest interpretation of our data is that in WT Pgp 
one of the two functionally equivalent sites becomes committed to hydrolysis in each cycle on a random basis, 
whereas in the single mutants commitment of the only functional site initiates every cycle.
Finally, a simplified kinetic model that distinguishes inward- and outward-facing states (Fig. 9; see full math-
ematical treatment in Supplementary Information) provides a semi-quantitative framework for interpretation of 
the data presented here, and offers some additional mechanistic insight. The model includes ATP-free (X0) and 
ATP-bound (X1) inward-facing states (associated with an open NBD dimer), and, for simplicity, depicts ATP 
binding as a single step assumed to be at rapid equilibrium. From the ATP-bound inward-facing conformation 
the transporter flips (with rate k1) to the ATP-bound outward-facing X2 state (associated with a closed NBD 
dimer). The model is very general, in that it does not specify (dotted arrow) the number and nature of inter-
mediate states between X2 and the final post-hydrolytic outward-facing state Xn, which eventually flips back to 
inward-facing state X0 upon NBD-dimer dissociation and release of hydrolysis products. Because UIC2 reactivity 
is believed to be uniformly low in all outward-facing states, the model allows UIC2 binding only to inward-facing 
conformations X0 and X1, yielding UIC2-bound states X0* and X1*, respectively. For simplicity, binding of UIC2 
and ATP are assumed independent – consistent with the fact that UIC2 recognizes an extracellular epitope22 
formed by the TMDs, the conformation of which is unlikely to sense mere binding of ATP to intracellular NBDs. 
The parameters of the model are as follows:
Kd;ATP is the dissociation constant of ATP from inward-facing Pgp,
Kd;UIC2 is the dissociation constant of the UIC2 antibody from inward-facing Pgp,
T1 is the average life time of the inward-facing conformation,
i.e., of compound state {X0; X1; 
⁎X0 ; 
⁎X1 },
Figure 9. Simplified model of the catalytic cycle of Pgp that distinguishes inward- and outward-facing 
states. 
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T1;min (= 1/k1) is T1 in the presence of zero [UIC2] and saturating [ATP], and
T2 is the average life time of the outward-facing conformation, i.e., of compound state {X2;… Xn}.
 v, is the turnover rate for ATP hydrolysis (or substrate transport), which is the inverse of the total cycle time 
T (= T1 + T2).
Despite its simplicity, the model is congruent with a broad range of existing data. (i) Consistent with the 
literature48,63, the scheme (Fig. 9) predicts that ATP-hydrolysis and ATP-dependent substrate transport by Pgp 
follow Michaelis-Menten type kinetics (see Supplementary Information Eqs 3–4). (ii) It further predicts that 
UIC2 should act as a mixed type inhibitor of Pgp-mediated ATP-hydrolysis and substrate transport, by lower-
ing the apparent Vmax and by increasing the apparent KM for ATP (see Supplementary Information Eqs 1–2 and 
5–6 for details). Indeed, UIC2 inhibits the efflux of Pgp substrates from multidrug resistant cells and signifi-
cantly increases the cytotoxicity of Pgp-transported drugs64,65. (iii) Consistent with our finding that ATP shifts 
Pgp into a low UIC2-affinity conformation in a concentration dependent manner (Fig. 1a), the scheme (Fig. 9) 
predicts that increasing [ATP] should diminish UIC2-labeling (by a fixed concentration of UIC2) following a 
Michaelis-Menten-type dose-response relationship, and the apparent affinity of ATP for competing UIC2 labe-
ling (KA) should be identical to the KM of ATP for ATP-hydrolysis and substrate transport observable at the same 
fixed [UIC2] (see Supplementary Information Eq. 7). (iv) Finally, the model predicts that the apparent affinity for 
UIC2 binding (KU) should be sensitive to ATP concentration (see Supplementary Information Eqs 9–11), which 
was verified in UIC2 titration experiments (Supplementary Fig. S5). These features qualified the model to be 
suitable for semi-quantitative interpretation of our results, and allowed us to draw some additional mechanistic 
conclusions.
First, our experiments provide two independent estimates of the fraction of time wild-type Pgp spends in the 
outward- vs. inward facing conformations under normal, hydrolytic conditions in saturating ATP (i.e., the ratio 
T2/T1;min). The first approach builds on the maximal shift in apparent affinity for UIC2 binding (KU) caused by 
very high concentrations of ATP. In the experiments documented in Supplementary Fig. S5 we determined KU at 
various different [ATP]. In the absence of ATP, KU reflects the antibody’s dissociation constant (Kd;UIC2), which 
was found to be ~2 μg/ml (~10 nM). In contrast, at very high [ATP], KU approaches ~20 μg/ml ≈ 10Kd;UIC2. This 
maximal ~10-fold shift in KU by high [ATP] indicates that in saturating [ATP] Pgp spends 90% of the total cycle 
time in the outward-facing (UIC2-dim) conformation ( ≈T T/ 92 ;1 min , see Supplementary Information Eq. 11). 
An independent estimate of T2/T1;min is obtained from the fraction of UIC2 label which resists even at saturating 
[ATP]. Applying a fixed [UIC2] of 10 μg/ml, equivalent to ≈ 5Kd;UIC2, we found that approximately one third of the 
UIC2 label persists at very high [ATP] (Fig. 1a), from which Eq. 8 (see Supplementary Information) predicts a 
ratio T2/T1;min of ~12. Thus, both approaches suggest that, in saturating ATP, WT Pgp spends the majority (> 90%) 
of the total cycle time in the outward-facing conformation (compound state {X2;… Xn} in the scheme (Fig. 9)). 
With other words, flipping from the ATP-bound inward-facing to the ATP-bound outward-facing conformation 
(step X1 → X2 in Fig. 9) is not the rate-limiting step of the overall cycle. A direct implication of this finding is that 
in Pgp substrate-mediated stimulation of ATPase turnover rate must reflect acceleration of some other step(s): 
mere speeding of step X1 → X2 could increase turnover rate by no more than ~10%. It will be interesting to estab-
lish how broadly this conclusion is applicable to other members of the ABC protein family. For instance, in the 
CFTR chloride ion channel (ABCC7) pore opening, believed to correspond to the transition from inward- to 
outward-facing, is no doubt the slowest step of the gating cycle, and is most robustly affected by channel phospho-
rylation, the primary mechanism for regulating CFTR activity (reviewed in66).
Second, the model allows comparison of the kinetics of the transport cycles of Walker A single mutants to that 
of WT. From the increased fraction of UIC2 label persisting in saturating ATP (~50%, Fig. 2b,c) we estimate a 
decreased ratio of ≈T T/ 62 ;1 min  (Supplementary Information Eq. 8), suggesting that in saturating [ATP], the 
fraction of time spent in the outward-facing conformation is somewhat decreased for single Walker A mutants 
relative to WT. This explains on one hand the higher apparent affinities for substrate binding observed for the 
single mutants (Fig. 7b,c vs. Fig. 7a; bars labeled “control”), but in part also the more modest suppression of sub-
strate affinities by 3–5 mM AMP-PNP (Fig. 8b; note also that for the single mutants 3–5 mM AMP-PNP is less 
than saturating (Fig. 2a and Supplementary Table S2)). In itself, the ~10 fold decrease in apparent affinity for ATP 
of the single mutants (Fig. 2b,c and Supplementary Table S2) would explain only a modest decrease in transport 
rate (to 80–90% of WT) at physiological ATP concentrations. Thus, to account for a transport rate which is only 
~10–15% of WT (Fig. 5), the average overall cycle time T of the single mutants must be significantly prolonged 
even in saturating ATP. Given our above estimate of T1;min/T2 ≈ 10 for WT-Pgp, a mere increase in T1;min (to yield 
≈T T/ 62 ;1 min ), would prolong the overall cycle time T only by ~6%: this falls far short of explaining the robust 
decline in transport rate (see Supplementary Information for more details). Two possible scenarios could account 
for this discrepancy. One possibility is that both T1;min and T2 are prolonged: in this view all cycles would go 
through ATP hydrolysis at the competent site, but both the rate of formation of the NBD dimer (k1) and the rate 
of ATP hydrolysis (step X2 → … Xn, overall rate k2) would be slowed. Alternatively, besides allosterically slowing 
ATP hydrolysis at the competent site, the major disturbance caused by single mutations could be destabilization 
of the NBD dimer, i.e., an increase in the slow rate (k-1) of reverse step X2 → X1. As a consequence, only ~1 out of 
6 sojourns in the X2 state would be terminated by ATP-hydrolysis (“productive” transport cycles), whereas in ~5 
out of 6 cases the reverse pathway would be taken (“fruitless” partial cycles)–with little change in the cycle time T 
itself. A similar mechanism, i.e., ~20% coupling between ATP-hydrolysis and pore opening events, has been sug-
gested for NBD1 Walker-A mutant K464A CFTR channels67.
In conclusion, we have shown that the high-to-low substrate affinity switch in Pgp coincides with the flipping 
of the TMDs to the outward-facing conformation, and that these events precede ATP hydrolysis. Double Walker 
A mutant Pgp is trapped in the high-affinity inward-facing conformation, but single mutants are capable of full 
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transport cycles albeit with reduced efficiency. Release from the vanadate-trapped low-affinity outward-facing 
conformation requires two functional composite sites. These results support random recruitment of the two cat-
alytic centers for ATP hydrolysis.
Materials and Methods
Chemicals. Cell culture media, supplements and chemicals were from Sigma-Aldrich (Budapest, Hungary). 
Fluorescent dyes including calcein acetoxymethyl ester (calcein-AM), BODIPY FL vinblastine (vinblastine-bod-
ipy; VBL-BPY) and Alexa 647 succinimidyl ester were purchased from Life Technologies, Inc. (Carlsbad, CA, 
USA). The UIC2 and 15D3 anti-Pgp mAbs were prepared from hybridoma supernatants using affinity chro-
matography and were > 97% pure by SDS/PAGE. Hybridoma cell lines were obtained from the American Type 
Culture Collections (Manassas, VA, USA). The UIC2 and 15D3 antibodies were labeled with Alexa 647 succin-
imidyl ester (A647) and separated from the unconjugated dye by gel filtration on a Sephadex G-50 column. The 
dye-to-protein labeling ratio was around 3 for each antibody preparation.
Cell lines. The NIH 3T3 mouse fibroblast cell line was a kind gift from Michael Gottesman (National Institutes 
of Health, Bethesda, MD). The MDCK II Madin-Darby canine kidney cell line was obtained from Balazs Sarkadi 
(Molecular Biophysics Research Group, Hungarian Academy of Sciences, Budapest, Hungary). The cells were 
grown as monolayer cultures at 37 °C in an incubator containing 5% CO2, and were maintained by regular passage 
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum, 2 mM 
L-glutamine, and 0.1 mg/ml penicillin-streptomycin cocktail.
Vector constructs. Sleeping Beauty transposon vectors containing the wild-type (WT), K433M, 
K1076M or the K433M/K1076M double mutant human MDR1 cDNA were constructed as follows. 
Site-directed mutagenesis was performed using the QuikChange II Site-Directed Mutagenesis Kit (Agilent 
Technologies, Santa Clara, CA, USA) on pAcUW-LMDR1 vector carrying the wild-type human MDR1 
cDNA. Mutations were generated according to the manufacturer’s instructions. The following oligonu-
cleotide primers were used: 5′-AAACAGTGGCTGTG GGATGAGCACAACAGTCCAGCTGA-3′ and 
5′-CAGCAGTGGCTGTGGGATGAGC ACAGTGGTCCAGCTCC-3′  for the K433M and K1076M 
mutations, respectively. The Sleeping Beauty (SB) transposon vector containing the cDNAs of EGFP and 
the puromycin resistance gene (PURO) in separate transcription cassettes, each driven by CAG pro-
moter, was kindly provided by Dr. Tamás István Orbán (Hungarian Academy of Sciences, Budapest, 
Hungary). Full-length wild-type MDR1 cDNA was amplified by PCR from pAcUW-LMDR1 vec-
tor with the following pair of primers: 5′-TAGAATACCGGTAGGTCGGAATGGATCTTGAA-3′ and 
5′-AGTGATGGATCCAACATCTCATACAGTCAGAG-3′ containing AgeI and BamHI restriction sites, 
respectively. The digested PCR product was cloned into the SB-EGFP-PURO transposon vector between the 
AgeI and BclI restriction sites, replacing EGFP, resulting in SB-MDR1-PURO vector. The PstI-BstBI restriction 
fragment of the MDR1 cDNA was then replaced in SB-MDR1-PURO with the mutated PstI-BstBI fragments 
derived from pAcUW-LMDR1K433M and pAcUW-LMDR1K1076M, resulting in SB-MDR1K433M-PURO 
and SB-MDR1K1076M-PURO vectors. The SB construct containing the K433M/K1076M double mutant MDR1 
cDNA was generated by replacing the 3242bp long HindIII-HindIII fragment in SB-MDR1K1076M-PURO with 
that of SB-MDR1K433M-PURO, resulting in SB-MDR1K433M/K1076M-PURO. Full-length MDR1 cDNAs were 
sequenced and mutations were confirmed in all SB constructs.
Establishment of transgenic cell lines. Cell lines stably expressing WT, K433M, K1076M, and K433M/
K1076M double mutant MDR1/P-glycoprotein were established by the Sleeping Beauty (SB) transposon-based 
gene delivery system, using the 100 fold hyperactive SB transposase68. NIH 3T3 mouse fibroblast and MDCK 
II canine kidney cells were co-transfected with the SB transposase and SB transposon vector constructs by 
Lipofectamine2000 reagent (Life Technologies, Carlsbad, CA, USA), in accordance with the manufacturer’s 
instructions. Briefly, 3 × 105 cells were seeded in 6-well-plates, 24 hours later cells were transfected with 2 μg 
vector DNA per well in a 10:1 ratio for the SB transposon and transposase constructs. 48 hours after transfection 
transgene positive cells were sorted by flow cytometry (FACS Aria High Speed Cell Sorter, Becton Dickinson) 
based on the cell surface expression of wild-type and mutant MDR1/P-glycoprotein. Protein expression was 
measured by antibody labeling using the human MDR1/P-glycoprotein specific monoclonal antibodies MRK16 
(Abnova GmbH, Heidelberg, Germany) or 15D3. To obtain homogenously expressing cell populations, sorting 
procedure was repeated 2 weeks after transfection.
Western blot analysis. Total cellular protein (2.5 μg/slot) was subjected to SDS-polyacrylamide gel elec-
trophoresis on 8% polyacrylamide gel and electro-blotted to 0.45 μm pore size nitrocellulose membrane (GE 
Healthcare Life Sciences, Little Chalfont, Buckinghamshire, UK). Pgp expression was detected by a mon-
oclonal anti-Pgp mAb (G-1, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and a goat anti-mouse 
HRP-conjugated IgG secondary antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), both applied 
at 1:5,000 dilution.
Permeabilization of cells with Staphylococcus aureus α-toxin or streptolysin-O. Staphylococcus 
aureus α -toxin and streptolysin-O (Sigma-Aldrich, Budapest, Hungary) binds to the plasma membrane of cells 
and forms ring-structured toxin hexamers that are permeable for small water soluble molecules including nucle-
otides69. Cell suspensions (1 × 107 cells/ml) were treated with 4 μg/ml α -toxin in phosphate-buffered saline (PBS) 
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in the presence of 1% bovine serum albumin (BSA) at 37 °C for 30 min, allowing permeabilization of approxi-
mately 50% of the cells (judged by propidium iodide (PI) positivity)25. The reaction was stopped with 40 ml of 
37 °C PBS and the cells were centrifuged for 7 min at 635 g at room temperature. Unbound toxin was removed by 
washing the cells 3 times with PBS and the cell pellet was re-suspended in PBS.
Cells grown attached to the bottom of Ibidi μ-Slide IV 0.4 (for confocal microscopy) were permeabilized by 
50 μg/ml Staphylococcus aureus α -toxin or 20 μg/ml (approx. 1300 U/ml) streptolysin-O in the presence of 10 mM 
DTT and Protease Inhibitor Cocktail at 37 °C for 60 min in HEPES buffer (20 mM HEPES, 123 mM NaCl, 5 mM 
KCl, 1.5 mM MgCl2, 1 mM CaCl2) containing 1% FCS (allowing permabilization of 60–80% of cells).
Determination of the apparent affinity of nucleotide binding. Permeabilized cells (1 × 106 ml−1) 
were pre-incubated for 20 min with nucleotides added in a broad concentration range and then further incu-
bated for 30 min with 10 μg/ml A647-conjugated UIC2 monoclonal antibody (all at 37 °C). UIC2 mAb binding 
to Pgp is a reversible reaction in the presence of ATP/Mg2+ (Supplementary Fig. S6), thus, UIC2 was applied at a 
quasi-saturating concentration (5Kd;UIC2; Supplementary Fig. S5) and the duration of the incubation period was 
sufficient to reach equilibrium binding of UIC2 (Supplementary Fig. S6).
When ATP was applied under hydrolysis conditions the concentration of the cells was decreased to 1.5 × 104 ml−1 
in order to reduce the consumption of ATP. Under these conditions the activity of Pgp and endogenous ATPases 
present in the permeabilized cells did not significantly reduce the concentration of ATP in the samples (less than 
3% of the ATP was converted to ADP).
To prevent ATP hydrolysis, ATP was added to permeabilized cells without Mg2+ in the presence of 5 mM 
EDTA. Alternatively, ATP was replaced by the non-hydrolysable ATP analogue AMP-PNP/Mg2+, or the experi-
ment was conducted on ice. In the latter case the labeling of cells with A647-conjugated UIC2 monoclonal anti-
body was carried out at 4 °C for 45 min. Following antibody labeling, samples were washed 3 times with ice-cold 
PBS and centrifuged for 7 min at 635 g at 4 °C. The UIC2-A647 fluorescence intensity of the cells was measured 
by flow cytometry and plotted as a function of the nucleotide concentration. To determine the apparent affinity 
of Pgp to the nucleotides (KA) data points were fitted with the four-parameter Hill function, where Fmin and Fmax 











Nucleotide trapping. The transition state of Pgp was stabilized by the addition of ATP/Mg2+ and vana-
date (Vi) or BeFx at 37 °C. Permeabilized cells were incubated with 100 μM (for WT) or 500 μM (for K433M and 
K1076M) ATP/Mg2+ and 0.5 mM Vi70 or BeFx (200 μM BeSO4 and 1 mM NaF) in the presence or absence of 
substrates in PBS at 37 °C. 500 μl aliquots were taken at regular intervals and washed twice with 5 ml ice-cold PBS 
containing Vi or BeFx at the same concentrations that were applied previously during incubation. Samples were 
re-suspended in ice-cold PBS and labeled with 10 μg/ml UIC2-A647 monoclonal antibody in the presence of the 
transition state analogue at 4 °C for 45 min. The UIC2-A647 fluorescence intensity of the samples (F) was plotted 
as a function of time (t). The t1/2 values representing the half-life of the UIC2-reactive Pgp conformation were 
calculated from an exponential fit of the data points according to the following equation:
= × +
− ×






where Fo i.e. the difference between the zero and infinite time point of the curve and c is the background fluores-
cence intensity of the cells.
Recovery from the Vi-trapped post-hydrolysis state. Permeabilized cells trapped in the presence of 
ATP/Mg2+ (100 μM for wild-type and 500 μM for single Walker A mutants) and 0.5 mM Vi were washed 3 times 
with ice-cold PBS and incubated in the presence or absence of ATP and/or substrates (verapamil, vinblastine) at 
37 °C. 500 μl aliquots containing 2 × 105 cells were taken at regular intervals and washed twice with 5 ml PBS. The 
aliquots were incubated in the presence of 200 μM N-ethyl-maleimide ((NEM) to avoid de novo disulphide bond 
formation between Walker A cysteines71) and labeled with 10 μg/ml UIC2-A647 at 37 °C for 15 min or at 4 °C for 
45 min. At the end of incubations the samples were washed three times with ice-cold PBS and kept on ice until 
measurement in the flow cytometer.
Calcein assay. Calcein accumulation was measured as described70. Briefly, cells (0.25 × 106 ml−1) were 
pre-incubated with a Pgp modulator cyclosporine A (CsA, 10 μM) for 10 min and then further incubated with 
100 nM calcein-AM at 37 °C for 30 min. Finally, samples were washed with ice-cold PBS containing 1% FCS 
(FCS-PBS) and kept on ice until measurement. Dead cells stained with PI were excluded from the analysis. 
Transport activity was described by the ratio of median fluorescence intensities of the CsA-treated and untreated 
samples.
Rhodamine 123 efflux assay. Cells (1 × 106 ml−1) were pre-loaded with 0.5 μM rhodamine 123 (R123) for 
30 min at 37 °C. Loading was terminated by chilling the tubes on ice; cells were washed three times with ice cold 
PBS (containing 8 mM glucose and 1% FCS, (gl-FCS-PBS), pH = 7.4). Efflux was initiated by re-suspending the 
cell pellet in gl-FCS-PBS pre-warmed to 37 °C. Efflux was monitored continuously over 5 minutes with a Becton 
Dickinson FACS Aria III flow cytometer at 37 °C using a temperature controlled sample injection chamber. Cells 
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were further incubated at 37 °C and samples were taken at 10, 20, 30, 60 and 120 min time points and their median 
fluorescence intensity was measured using the same settings of the cytometer. Viable cells were selected by PI 
exclusion. Upon continuous monitoring of R123 efflux mean fluorescence intensities were computed for 10 sec-
ond time intervals. Median fluorescence intensities were displayed as a function of time and the first order rate 
constants (k-values) were calculated from an exponential fit of the data points according to Eq. 3, where a is initial 
loading (i.e. the difference between the zero and infinite time point of the curve), t is the time in minutes, y is 
mean fluorescence intensity at t time point, and c is background fluorescence intensity of the cells.
= × +− ×y a e c (3)k t
Vinblastine-bodipy staining. Cells were plated in 8-well Ibidi μ-Slide (Ibidi GmbH, Martinsried, 
Germany) two days before the experiments to obtain nearly confluent cultures. The samples were pre-incubated 
with the following agents: Na-azide (10 mM) and 2-deoxy D-glucose (8 mM), Vi (2 mM) or NEM (50 μM) for 
30 min and then further incubated with 100 nM vinblastine-bodipy (VBL-BPY) and 30 μg/ml A647-conjugated 
15D3 anti-Pgp antibody for another 30 min at 37 °C.
Flow cytometry. Calcein accumulation and R123 efflux measurements were carried out on a Becton 
Dickinson FACSAriaTM III Cell Sorter (Becton Dickinson, Mountain View, CA, USA). Calcein and R123 were 
excited by the 488 nm line of a solid state laser and the emitted light was detected using a 502 nm dichroic mirror 
and a 530/30 nm band-pass filter. PI was excited by the 562 nm line of a solid state laser and the emitted light was 
detected applying a 590 nm dichroic mirror and a 595/50 nm band-pass filter. In case of continuous monitoring 
of R123 efflux the sample injection chamber was kept at 37 °C, while in other cases it was at 4 °C. Cytofluorimetric 
data were analysed by using FCS Express 4 Research Edition (De Novo Software, Glendale, CA, USA).
UIC2-A647 labeling of permeabilized cells was measured by using a Becton Dickenson FACS Array flow 
cytometer; the data were analysed with the BDIS CellQuest software. A 635 nm laser was used for the excitation 
of the Alexa 647 dye and the fluorescence was detected in the red channel (661/16 nm), while the 532 nm laser 
was used for the excitation of PI (detected at 585/42 nm). Cell debris was excluded from analysis on the basis of 
FSC and SSC signals. The median fluorescence indicating UIC2 reactivity was determined in PI positive cells.
Confocal laser scanning microscopy. Cellular localization of Pgp and VBL-BPY staining was studied 
by a three-laser confocal laser scanning microscope (Olympus FluoView 1000 confocal microscope based on 
an inverted IX-81 stand with an UPlansAPo 60 × NA 1.35 oil immersion objective, Hamburg, Germany). The 
488-nm blue line of an argon-ion laser, and the 543-nm green and the 633-nm red helium-neon laser lines were 
used for the excitation of VBL-BPY, PI and Alexa 647, respectively. Fluorescence intensities were detected in 
the spectral ranges of 500–530 nm, 555–655 nm and 655–755 nm, respectively. To assess the co-localization 
of VBL-BPY (green) and Alexa 647-conjugated 15D3 (red) fluorescence signals, single optical slices of apical 
membrane surfaces were recorded for double-labeled cells. The pattern and extent of co-localization in the sec-
tions were determined by using the cross-correlation scattergrams of the green and red pixels of the images. 
Co-localization indices were determined from 30–50 cells (in three independent experiments). The Pearson’s 
co-localization index (CI) provides a reliable estimate on the extent of fluorescence co-localization: CI values 
close to zero indicate no or a very low degree, while CI ≥ 0.5 reflects a high degree of co-localization, whereas the 
CI = 1 value would correspond to a full overlap between the two colours in each pixel of the image.
In case of permeabilized cells VBL-BPY flurescence intensity was determined in pixels representing the apical 
plasma membrane selected on the basis of 15D3-Alexa-647 fluorescence intensity exceeding the threshold of 300 
above background intensity.
Statistical analysis. Data were analysed using SigmaStat (version 3.1, SPSS Inc., Chicago, IL, USA) and are 
presented as means ± SD. Comparison of two groups was carried out by unpaired t-test, statistical significance 
in the case of three or more groups was assessed using analysis of variance (ANOVA), applying the Holm-Sidak 
multiple comparison test for post hoc pair-wise comparison of the data. In the case of unequal variances Dunnett 
T3 post hoc pair-wise comparison method was used. Differences were considered significant at P < 0.05.
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